Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
Outlook Therapeutics secured FDA approval for LYTENAVA for the treatment of wet AMD, marking the first FDA-approved ophthalmic formulation of bevacizumab in the U.S. The drug targets a roughly $8.5 billion U.S. retina market and benefits from an anticipated 12 years of Reference Product Exclusivity under the BPCIA.
Key figures
- Drug Name
- LYTENAVA™ (bevacizumab-vikg)
- Market size usd
- 8500000000
- Exclusivity years
- 12
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.